|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 40.32 EUR | +0.58% |
|
+1.97% | +9.17% |
| 03-16 | UBS sees 'preponderance of opportunities' for Bayer, upgrades stock to 'Buy' | DP |
| 03-16 | BAYER AG : Barclays remains its Buy rating | ZD |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5d. change | Varia. Jan 1. | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| BAYER AG | Other Pharmaceuticals | +0.80% | +1.97% | +9.17% | +69.84% | -23.49% | 45.22B |  |  |  |
Technical Rankings Surperformance
- Stock Market
- Equities
- BAYN Stock
- Charts Bayer AG
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition